EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling

Fei Luo, Mingda Zhang, Bowen Sun, Chenxin Xu, Yi Yang, Yingwen Zhang, Shanshan Li, Guoyu Chen, Ceshi Chen, Yanxin Li, Haizhong Feng

Molecular Cancer · 22.03.2024 · 23 (1)

DOI: 10.1186/s12943-024-01975-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cancer, online erschienen am 22.03.2024. Verfasst von Fei Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shan…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, the Shanghai Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer stem-like cell is a key barrier for therapeutic resistance and metastasis in various cancers, including breast cancer, yet the underlying mechanisms are still elusive. Through a genome-wide lncRNA expression profiling, we identified that LINC00115 is robustly upregulated in chemoresistant breast cancer stem-like cells (BCSCs).

Methods

LncRNA microarray assay was performed to document abundance changes of lncRNAs in paclitaxel (PTX)-resistant MDA-MB-231 BCSC (ALDH + ) and non-BCSC (ALDH − ). RNA pull-down and RNA immunoprecipitation (RIP) assays were performed to determine the binding proteins of LINC00115. The clinical significance of the LINC00115 pathway was examined in TNBC metastatic lymph node tissues. The biological function of LINC00115 was investigated through gain- and loss-of-function studies. The molecular mechanism was explored through RNA sequencing, mass spectrometry, and the CRISPR/Cas9-knockout system. The therapeutic potential of LINC00115 was examined through xenograft animal models.

Results

LINC00115 functions as a scaffold lncRNA to link SETDB1 and PLK3, leading to enhanced SETDB1 methylation of PLK3 at both K106 and K200 in drug-resistant BCSC. PLK3 methylation decreases PLK3 phosphorylation of HIF1α and thereby increases HIF1α stability. HIF1α, in turn, upregulates ALKBH5 to reduce m 6 A modification of LINC00115, resulting in attenuated degradation of YTHDF2-dependent m 6 A-modified RNA and enhanced LINC00115 stability. Thus, this positive feedback loop provokes BCSC phenotypes and enhances chemoresistance and metastasis in triple-negative breast cancer. SETDB1 inhibitor TTD-IN with LINC00115 ASO sensitizes PTX-resistant cell response to chemotherapy in a xenograft animal model. Correlative expression of LINC00115, methylation PLK3, SETDB1, and HIF1α are prognostic for clinical triple-negative breast cancers.

Conclusions

Our findings uncover LINC00115 as a critical regulator of BCSC and highlight targeting LINC00115 and SETDB1 as a potential therapeutic strategy for chemotherapeutic resistant breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingTriple Negative Breast NeoplasmsAnimalsHumansCell Line, TumorBreastSignal TransductionPaclitaxelDisease Models, AnimalNeoplastic Stem CellsHistone-Lysine N-MethyltransferasePolo-like KinasesProtein Serine-Threonine KinasesTumor Suppressor Proteins

Stichwörter der Autor:innen

Cancer stem-like cellsHIF1αLINC00115Lysine methylationTherapeutic resistanceTriple-negative breast cancer

Substanzen

RNA, Long NoncodingPaclitaxelSETDB1 protein, humanHistone-Lysine N-MethyltransferasePLK3 protein, humanPolo-like KinasesProtein Serine-Threonine KinasesTumor Suppressor Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of M…
  • Academy of Biomedical Engineering, the Third Affiliated Hospital, Kunming Medical University, Kunming, 650500, China. chenc@kmmu.edu.cn.
  • State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • the Shanghai Municipal Science and Technology Commission
  • the Program of Shanghai Academic/Technology Research Leader

Zitieren

APA

Luo, F., Zhang, M., Sun, B., Xu, C., Yang, Y., Zhang, Y., Li, S., Chen, G., Chen, C., Li, Y., & Feng, H. (2024). LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. Molecular Cancer, 23(1). https://doi.org/10.1186/s12943-024-01975-3

Vancouver

Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang Y, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. Molecular Cancer. 2024;23(1). doi:10.1186/s12943-024-01975-3

BibTeX
@article{Luo2024,
  author = {Luo, Fei and Zhang, Mingda and Sun, Bowen and Xu, Chenxin and Yang, Yi and Zhang, Yingwen and Li, Shanshan and Chen, Guoyu and Chen, Ceshi and Li, Yanxin and Feng, Haizhong},
  title = {LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling},
  journal = {Molecular Cancer},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.1186/s12943-024-01975-3}
}
Kostenlos starten →